 Erin Harvey
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Asthmatic Agents | 9 | 2025 | 266 | 2.510 |
Why?
| | Asthma | 15 | 2025 | 1889 | 1.980 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 816 | 1.700 |
Why?
| | Viruses | 7 | 2025 | 162 | 1.670 |
Why?
| | RNA Viruses | 4 | 2025 | 76 | 1.510 |
Why?
| | Australia | 19 | 2025 | 304 | 1.450 |
Why?
| | Adrenal Cortex Hormones | 5 | 2025 | 496 | 0.990 |
Why?
| | Palaemonidae | 1 | 2022 | 1 | 0.790 |
Why?
| | Carps | 1 | 2022 | 4 | 0.780 |
Why?
| | Nodaviridae | 1 | 2022 | 4 | 0.780 |
Why?
| | Ticks | 2 | 2020 | 30 | 0.760 |
Why?
| | Eosinophils | 2 | 2025 | 322 | 0.740 |
Why?
| | Siphonaptera | 1 | 2019 | 14 | 0.620 |
Why?
| | Phylogeny | 8 | 2025 | 1007 | 0.620 |
Why?
| | Phascolarctidae | 1 | 2019 | 1 | 0.610 |
Why?
| | Chlamydia | 1 | 2019 | 10 | 0.600 |
Why?
| | DNA Viruses | 1 | 2019 | 23 | 0.600 |
Why?
| | Microbial Interactions | 1 | 2019 | 18 | 0.600 |
Why?
| | Tick-Borne Diseases | 1 | 2019 | 12 | 0.600 |
Why?
| | RNA Virus Infections | 1 | 2019 | 20 | 0.600 |
Why?
| | Genome, Viral | 2 | 2024 | 222 | 0.570 |
Why?
| | Chlamydia Infections | 1 | 2019 | 78 | 0.560 |
Why?
| | Lyme Disease | 1 | 2019 | 61 | 0.560 |
Why?
| | Anxiety | 1 | 2025 | 1069 | 0.560 |
Why?
| | Biodiversity | 3 | 2025 | 415 | 0.550 |
Why?
| | Coinfection | 1 | 2019 | 138 | 0.540 |
Why?
| | Registries | 8 | 2025 | 2054 | 0.520 |
Why?
| | Depression | 1 | 2025 | 1467 | 0.480 |
Why?
| | Marsupialia | 3 | 2025 | 7 | 0.430 |
Why?
| | Cochlear Implantation | 2 | 2025 | 75 | 0.410 |
Why?
| | Speech Perception | 2 | 2025 | 81 | 0.410 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2864 | 0.390 |
Why?
| | Metagenomics | 3 | 2024 | 177 | 0.370 |
Why?
| | Administration, Oral | 2 | 2025 | 790 | 0.340 |
Why?
| | Virology | 2 | 2021 | 36 | 0.320 |
Why?
| | Quality of Life | 5 | 2025 | 2954 | 0.310 |
Why?
| | Animals, Wild | 2 | 2020 | 62 | 0.310 |
Why?
| | Microsurgery | 2 | 2025 | 76 | 0.270 |
Why?
| | Neuroma, Acoustic | 2 | 2025 | 51 | 0.260 |
Why?
| | Coral Reefs | 1 | 2025 | 10 | 0.230 |
Why?
| | Fishes | 1 | 2025 | 111 | 0.220 |
Why?
| | Cichlids | 1 | 2024 | 4 | 0.220 |
Why?
| | Remission Induction | 4 | 2025 | 295 | 0.220 |
Why?
| | Radiosurgery | 2 | 2025 | 389 | 0.210 |
Why?
| | Animals | 11 | 2025 | 37351 | 0.210 |
Why?
| | Treatment Outcome | 7 | 2025 | 10961 | 0.200 |
Why?
| | Pulmonary Eosinophilia | 1 | 2022 | 27 | 0.190 |
Why?
| | Larynx | 1 | 2023 | 61 | 0.190 |
Why?
| | Respiration Disorders | 1 | 2023 | 78 | 0.190 |
Why?
| | Nasal Polyps | 1 | 2022 | 61 | 0.190 |
Why?
| | Middle Aged | 11 | 2025 | 33864 | 0.180 |
Why?
| | Capsid Proteins | 1 | 2022 | 93 | 0.180 |
Why?
| | Aged | 8 | 2025 | 24236 | 0.180 |
Why?
| | Otolaryngology | 1 | 2023 | 98 | 0.180 |
Why?
| | Fires | 1 | 2022 | 89 | 0.170 |
Why?
| | Trypanosoma | 1 | 2020 | 8 | 0.170 |
Why?
| | Spheniscidae | 1 | 2020 | 2 | 0.170 |
Why?
| | Biological Products | 1 | 2023 | 229 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 254 | 0.160 |
Why?
| | Faculty, Medical | 1 | 2023 | 290 | 0.160 |
Why?
| | Humans | 22 | 2025 | 139062 | 0.160 |
Why?
| | Insect Vectors | 1 | 2019 | 38 | 0.150 |
Why?
| | Clinical Audit | 1 | 2019 | 14 | 0.150 |
Why?
| | Borrelia | 1 | 2019 | 9 | 0.150 |
Why?
| | Lizards | 1 | 2019 | 45 | 0.150 |
Why?
| | Leadership | 1 | 2023 | 396 | 0.140 |
Why?
| | Classification | 1 | 2018 | 41 | 0.140 |
Why?
| | Remote Sensing Technology | 1 | 2018 | 18 | 0.140 |
Why?
| | Patient Care Management | 1 | 2018 | 55 | 0.140 |
Why?
| | Male | 13 | 2025 | 68324 | 0.140 |
Why?
| | Transcriptome | 2 | 2021 | 971 | 0.140 |
Why?
| | Bacteria | 1 | 2025 | 868 | 0.140 |
Why?
| | Female | 14 | 2025 | 74074 | 0.140 |
Why?
| | Eye | 1 | 2019 | 111 | 0.140 |
Why?
| | Disease Progression | 3 | 2020 | 2741 | 0.140 |
Why?
| | Linear Models | 1 | 2020 | 856 | 0.140 |
Why?
| | Air Pollutants | 1 | 2022 | 425 | 0.130 |
Why?
| | Adult | 9 | 2025 | 38389 | 0.130 |
Why?
| | Microbiota | 1 | 2025 | 760 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2019 | 532 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 239 | 0.120 |
Why?
| | Biomedical Research | 1 | 2019 | 699 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1757 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2019 | 1088 | 0.090 |
Why?
| | Obesity | 2 | 2022 | 3002 | 0.080 |
Why?
| | Rats | 1 | 2019 | 5598 | 0.080 |
Why?
| | Antarctic Regions | 2 | 2020 | 26 | 0.080 |
Why?
| | Ecosystem | 2 | 2024 | 578 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1656 | 0.060 |
Why?
| | Endangered Species | 1 | 2025 | 17 | 0.060 |
Why?
| | Ear Neoplasms | 1 | 2025 | 9 | 0.060 |
Why?
| | Neurilemmoma | 1 | 2025 | 23 | 0.060 |
Why?
| | Ear, Inner | 1 | 2025 | 50 | 0.050 |
Why?
| | Lakes | 1 | 2024 | 27 | 0.050 |
Why?
| | Tanzania | 1 | 2024 | 57 | 0.050 |
Why?
| | Metagenome | 1 | 2024 | 150 | 0.050 |
Why?
| | Cochlear Implants | 1 | 2024 | 89 | 0.050 |
Why?
| | Omalizumab | 1 | 2023 | 40 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 197 | 0.050 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2021 | 99 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 419 | 0.040 |
Why?
| | Smoke | 1 | 2022 | 145 | 0.040 |
Why?
| | DNA, Protozoan | 1 | 2020 | 32 | 0.040 |
Why?
| | Ranidae | 1 | 2020 | 14 | 0.040 |
Why?
| | Minority Groups | 1 | 2023 | 274 | 0.040 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2020 | 27 | 0.040 |
Why?
| | Vertebrates | 1 | 2020 | 63 | 0.040 |
Why?
| | Passeriformes | 1 | 2020 | 34 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5892 | 0.040 |
Why?
| | Logistic Models | 1 | 2025 | 2089 | 0.040 |
Why?
| | Particulate Matter | 1 | 2022 | 317 | 0.040 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 118 | 0.040 |
Why?
| | International Cooperation | 1 | 2019 | 204 | 0.040 |
Why?
| | Australasia | 1 | 2018 | 2 | 0.040 |
Why?
| | Medication Therapy Management | 1 | 2019 | 77 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2018 | 37 | 0.040 |
Why?
| | Humpback Whale | 1 | 2018 | 2 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 541 | 0.030 |
Why?
| | Internationality | 1 | 2018 | 158 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2022 | 568 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2025 | 3408 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3584 | 0.030 |
Why?
| | Specialization | 1 | 2018 | 148 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 381 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 650 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15922 | 0.030 |
Why?
| | Delphi Technique | 1 | 2018 | 290 | 0.030 |
Why?
| | Biological Evolution | 1 | 2020 | 486 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 538 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 679 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 620 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2846 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3160 | 0.030 |
Why?
| | RNA | 1 | 2020 | 930 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5537 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2746 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 10426 | 0.010 |
Why?
|
|
Harvey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|